title: Sacubitril/valsartan (Entresto) for heart failure.
mesh_terms: D000613:Aminobutyrates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D004338:Drug Combinations; D004347:Drug Interactions; D006333:Heart Failure / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D015260:Neprilysin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D013318:Stroke Volume / Q000187:drug effects; D013777:Tetrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D002316:Cardiotonic Agents; D004338:Drug Combinations; D011480:Protease Inhibitors; D013777:Tetrazoles; D000068756:Valsartan; D015260:Neprilysin; C549068:sacubitril and valsartan sodium hydrate drug combination